[JCOGの基本情報] 研究実績 - 婦人科腫瘍グループ：日本臨床腫瘍研究グループ（JCOG:Japan Clinical Oncology Group）

JCOGの基本情報 > 研究実績 > 婦人科腫瘍グループ

婦人科腫瘍グループ

更新日：2010年8月31日

論文
1. 委員会承認の治療研究
  
  JCOG9412
  
  R Tsunematsu, H Yoshikawa, M Yakushiji, et al.: Phase II study of dose-intensive cyclophosphamide, doxorubicin and cisplatin (CAP) with G-CSF in patients with advanced epithelial ovarian cancer. International Journal of Gynecological Cancer. 7(S2): 125, 1997.
  
  JCOG0206
  
  T Onda, T Kamura, N Ishizuka, et al.: Feasibility study of neoadjuvant chemotherapy followed by interval cytoreductive surgery for stage III/IV ovarian, tubal and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0206. Jpn J Clin Oncol. 34(1):43-45, 2004.
  
  T Onda, H Kobayashi, T Nakanishi, et al.: Feasibility study of neoadjuvant chemotherapy followed by interval debulking surgery for stage III/IV ovarian, tubal, and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0206. Gynecol Oncol 113: 57-62, 2009.
  
  JCOG0602
  
  T Onda, K Matsumoto, T Shibata et al.: Phase III trial of upfront debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0602. Jpn J Clin Oncol. 38: 74-7, 2008.
  
  JCOG0505
  
  I Saito, R Kitagawa, H Fukuda, et al.: A Phase III Trial of Paclitaxel plus Carboplatin Versus Paclitaxel plus Cisplatin in Stage IVB, Persistent or Recurrent Cervical Cancer: Gynecologic Cancer Study Group / Japan Clinical Oncology Group Study (JCOG0505).Jpn J Clin Oncol. 40(1): 90-93, 2010.
2. グループ代表者管理の治療研究
  - Y Kaku, H Yoshikawa, H Tsuda, et al.: Conservative therapy for adenocarcinoma and atypical endometrial hyperplasia of the endometrium in young woman: central pathologic review and treatment outcome. Cancer Lett. 167: 39-48, 2001.
  - J Akahira, H Yoshikawa, Y Shimizu, et al.: Prognostic factors of stage IV epithelial ovarian cancer: A multicenter retrospective study. Gynecol Oncol. 81: 398-403, 2001.
  - K Yamamoto, H Yoshikawa, K Shiromizu, et al.: Pulmonary metastasectomy for uterine cervical cancer: A multivariate analysis. Annals of Thoracic Surgery. 77(4): 1179-1182, 2004.
  - T Kodaira, K Kuzuya, et al.: Long-term clinical outcomes of postoperative pelvic radiotherapy with or without prophylactic paraaortic irradiation for stage I-II cervical carcinoma with postive lymph nodes retrospective analysis of predictive variables regarding survival and failure patterns. Am J Clin Oncol .7: 140-148, 2004.
  - T Minaguchi, H Yoshikawa, et al.: Association of PTEN mutation with HPV-negative adenocarcinoma of the uterine cervix. Cancer Lett.210: 57-62,2004.
  - H Xiao, T Kamura, et al.: Co-expression of Y Box- binding protein-1 and P-glycoprotein as a prognostic marker for survival inepithelial ovarian cancer.Gynecol Oncol.93: 287-291, 2004.
  - T Onda, N Katsumata, R Tsunematsu et al.: Cisplatin, paclitaxel and escalating doses of doxorubicin (TAP) in advanced ovarian cancer: a phase I trial. Jpn J Clin Oncol. 34: 540-6, 2004.
  - T Kasamatsu, T Onda, T Yamada, et al.: Clinical aspects and prognosis of pelvic recurrence of cervical carcinoma. Int J Gynaecol Obstet., 89 : 39-44, 2005
  - K Matsumoto, N Katsumata, Y Yamanaka, et al.: The safety and efficacy of the weekly dosing of irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer. Gynecol Oncol.100 (2) : 412-416, 2006.
  - K Yonemori, N Katsumata, N Yamamoto, et al.: A phase I study and pharmacologic evaluation of irinotecan and carboplatin for patients with advanced ovarian carcinoma who previously received platinum-containing chemotherapy. Cancer. 15;104(6) : 1204-1212, 2005.
  - I Konishi : Review: Gonadotropins and ovarian carcinogenesis: a new area of basic research and its clinical implications. Int J Gynecol Cancer 16: 16-22, 2006.
  - K Ushijima:Management of retroperitoneal lymph nodes in the treatment of ovarian cancer.Int J Oncol.12:181-186,2007.
  - K Ushijima,H Yahata,H Yoshikawa, et al.: Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. J Clin Oncol.25(19):2798-2803,2007.
  - S Nishio,T Sugiyama,T Shouji, et al.: Pilot study evaluating the efficacy and toxicity of irinotecan plus oral etoposide for platinum-and taxane-resistant epithelial ovarian cancer. Gynecol Oncol.in press,2007.
  - S Nishio,T Sugiyama,R Kitagawa, et al.: Pilot study evaluating the efficacy and toxicity of irinotecan plus oral etoposide for platinum -a nd taxane - resistant epithelial ovarian cancer. Gynecol Oncol.106 : 342 -347,2007.
  - K Uno,T Satoh, H Yoshikawa, et al.: Tissue factor expression as a possible determinant of thromboembolism in ovarian cancer. Br J Cancer. 96(2):290-295,2007.
  - K Ohara,H Yoshikawa, et al.: Explanation for the failure of neoadjuvant chemotherapy to improve outcomes after radiotherapy for locally advanced uterine cervical cancer from the standpoint of the tumor regression rate. Radiat Med. 25:53-59,2007.
  - T Satoh ,H Yoshikawa, et al.: High incidence of silent venous thromboembolism before treatment in ovarian cancer. Br J Cancer.97(8):1053-1057,2007.
  - T Saito, et al.: Management of lymph nodes in the treatment of vulvar cancer. Int J Clin Oncol.12:187-191,2007.
  - T Ota,K Takizawa, et al.: Treatment of squamous cell carcinoma of the uterine cervix with radiation therapy alone; long-term survival, late complications, and incidence of second cancers. Br J Cancer.97:1058 -1062 ,2007.
  - S Nishio,T Kasamatsu, et al.: Analysis of the clinicopathological prognosis of stage IVb cervical carcinoma.Oncol Rep.19:497-503,2008.
  - M Hirakawa ,T Toita , et al.: Predictive factor of distant recurrence in locally advanced　squamous cell carcinoma of the cervix treated with concurrent chemoradiotherapy. Gynecol Oncol.108 :126-9,2008.
  - T Kasamatsu, T Onda, Y Sasajima, et al.: Prognostic significance of positive peritoneal cytology in adenocarcinoma of the uterine cervix. Gynecol Oncol. 115(3):488-92, 2009.
  - T Kasamatsu, T Onda, M Sawada, et al.: Radical hysterectomy for FIGO stage IIB cervical cancer: clinicopathological characteristics and prognostic evaluation. Gynecol Oncol. 114(1):69-74, 2009.
  - T Kasamatsu, T Onda, M Sawada, et al.: Radical hysterectomy for FIGO stage I-IIB adenocarcinoma of the uterine cervix. Br J Cancer. 100(9):1400-5, 2009.
  - T Satoh, M Hatae, Y Watanabe, et al.: Outcomes of Fertility-Sparing Surgery for Stage I Epithelial Ovarian Cancer: A Proposal for Patient Selection. J Clin Oncol. 28(10):1727-1732, 2010.
3. 附随研究等
  - T Saito,K Kato :Management of lymph nodes in the treatment of vulvar cancer.Int J Clin Oncol 12:285-290,2006.
  - T Kasamatsu et al.:Surgical treatment for neuroendocrine carcinoma of the uterine cervix. Int J Gynecol Obstet .in press,2006.
4. 総説・解説
  - 恩田貴志：Neoadjuvant Therapy：卵巣癌、癌治療と宿主. 14：65-71, 2002.
  - 勝俣範之、喜多川亮、山中康弘：「子宮頸癌に対するNeoadjuvant chemotherapy」:癌治療と宿主. 14(4)： 307-314, 2002.
  - 恩田貴志：固形癌に対するNeoadjuvant Therapy：進行卵巣癌に対するNeoadjuvant chemotherapy, 血液・腫瘍科. 46： 529-537, 2003.
  - K Ohara, H Yoshikawa, et al. : Use of the small pelvic field instead of the classic whole pelvic field in postoperative radiotherapy for cervical cancer: reduction of adverse events. Int Jpn Radiat Oncol Biol Phys. 60(1): 258-264, 2004.
  - 恩田貴志：【卵巣がん治療のCONTROVERSY】ネオアジュバント化学療法の意義. 産科と婦人科. 71: 1173-1178, 2004.
  - 勝俣範之: 婦人科癌に関する臨床試験の現状. がん臨床試験の米国での現状について. 日本婦人科腫瘍学会雑誌. 22: 181, 2004.
  - 恩田貴志: 婦人科癌に関する臨床試験の現状. JCOGにおける多施設共同試験, 日本婦人科腫瘍学会雑誌. 23 : 36-41, 2005.
  - 勝俣範之: 卵巣癌治療の最新情報と将来展望. 再発卵巣がんの化学療法. 日本産科婦人科学会関東連合地方部会会報. 42: 295, 2005.
  - 勝俣範之:「卵巣癌の化学療法」週間医学のあゆみ. がんの化学療法. 医歯薬出版株式会社. 215:449-454, 2005.
  - 喜多川亮、嘉村敏治：子宮頸がんの集学的治療に用いる化学療法としてシスプラチンとパクリタキセル併用の高い有用性を示唆する論文.Mebio Oncology. 2(1): 81-83, 2005.
  - 牛嶋公生: 若年者子宮体癌, 内膜異型増殖症に対しての妊孕性温存治療, 日本婦人科腫瘍学会雑誌. 23 : 401-406, 2005.
  - 恩田貴志: 婦人科癌に関する臨床試験の現状. JCOGにおける多施設共同試験、日本婦人科腫瘍学会雑誌. 23 : 36-41, 2005.
  - 勝俣範之:わが国の婦人科がんにおける研究者主導臨床研究の現状:臨床薬理37(1): 65-69, 2006.
  - 恩田貴志：[特集]Adjuvant and Neoadjuvant Chemotherapy-Standardなもの、Standardになり得るものとは-. Mebio Oncology. 3: 58-65, 2006.
  - 西尾真, 勝俣範之: 臨床試験（治験）よくわかる卵巣癌のすべて. 永井書店. 398-403, 2007.
  - 堀田洋介, 勝俣範之: 子宮体がんに対する化学療法. 産婦人科の世界. 59(11):1003-1010, 2007
  - 勝俣範之: 子宮頸癌に対する集学的治療標準的治療の確立を目指して進行・再発子宮頸がんに対する化学療法. 日本癌治療学会誌. 42: 238, 2007.
  - 谷岡真樹, 勝俣範之: 【婦人科がん再発への対応】婦人科がん再発の治療戦略総論化学療法. 産科と婦人科. 74: 1149-1154, 2007.
  - 恩田貴志：【Neoadjuvant Therapyの適応と効用・II】卵巣癌. 癌と化学療法. 34: 1735-1739、2007.
  - 恩田貴志：【婦人科がん治療の臨床試験新たなエビデンスを求めて】進行卵巣癌に対するNAC化学療法 NAC vs 術後. 産婦人科の実際. 57: 2147-2155, 2008.
  - 勝俣範之: 難治性卵巣癌の治療. 日本婦人科腫瘍学会雑誌. 26: 373-380, 2008.
  - 植原貴史、勝俣範之: 固形がんにおける薬物療法の進歩婦人科がん. 癌と化学療法. 35(9): 1488-1494, 2008.
  - 柴田剛志, 勝俣範之: 【婦人科がん診療のリスクマネージメント】標準治療, 臨床試験に関する問題点がんの臨床試験. 産婦人科の実際. 57: 1888-1893, 2008.
  - 小谷凡子, 勝俣範之: 「第三相試験」がん薬物療法学. 日本臨床. 67: 408-413, 2009.
  - 本多和典, 勝俣範之: 「卵巣癌」がん薬物療法学. 日本臨床. 67: 695-699, 2009.
  - T Onda, H yoshikawa: A phase III randomized trial comparing neoadjuvant chemotherapy and upfront debulking surgery is indispensable as a basis for changing the standard treatment of advanced Müllerian cancer. Gynecol Oncol. 114: 371-372, 2009.
主な学会発表
1. 委員会承認の治療研究
  - JCOG0206
    T Onda et al.:Feasibility study of neoadjuvant chemotherapy (NAC) followed by interval debulking surgery (IDS) for stage III/IV ovarian, tubal and peritoneal cancers: Japan ClinicalOncology Group study JCOG0206. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20Supplement), 2006.
  - JCOG0102
    N. Katsumata, H. Yoshikawa, T. Hirakawa, et al.: Phase III randomized trial of neoadjuvant chemotherapy (NAC) followed by radical hysterectomy (RH) versus RH for bulky stage I/II cervical cancer (JCOG 0102). Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, 18S (June 20 Supplement): 5013, 2006.
    
    N. Katsumata, H. Yoshikawa, H. Kobayashi, et al.: Phase III randomized trial of neoadjuvant chemotherapy (NAC) followed by radical hysterectomy (RH) versus RH for bulky stage I/II cervical cancer: Update of Japan Clinical Oncology Group (JCOG) Protocol 0102. J Clin Oncol 28:7s (suppl; abstr 5047), 2010.
  - JCOG0503
    K. Matsumoto, N. Katsumata, I. Saito, et al.: A phase II trial of oral etoposide and intravenous irinotecan for patients with platinum-resistant and taxane-pretreated ovarian cancer (JCOG0503). J Clin Oncol 28:7s, (suppl; abstr TPS259), 2010.
2. グループ代表者管理の治療研究
  - T. Onda, N. Katsumata, T. Yasugi et al.: Cisplatin, Paclitaxel and Escalating Doses of Doxorubicin (TAP) in Advanced Ovarian Cancer. A Phase I-II Trial. Proc Am Soc Clin Oncol 21(Part 1 of 2), 217a (abstract #867), 2002.
  - R. Kitagawa, N. Katsumata, Y. Yamanaka, et al.: Phase II trial of paclitaxel (T) and carboplatin (C) in patients with recurrent or metastatic cervical carcinoma. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 22, No 14s (July 15 Supplement): 5048, 2004.
3. 附随研究等
  - なし
4. 総説・解説
  - 恩田貴志：JCOGにおける臨床試験. シンポジウム－婦人科癌に関する臨床試験の現状－、第36回日本婦人科腫瘍学会学術集会. 2004年.
  - 勝俣範之: 第42回日本癌治療学会総会パネルディスカッション医師主導型臨床試験の現状と今後の展開「婦人科がん臨床試験グループの現状と今後の展開」.2004年
  - 恩田貴志 : わが国の臨床試験は-卵巣癌初回治療-進行卵巣癌に対する術前化学療法 . 第43回日本癌治療学会 . 2005年

その他の研究グループ

トップへ戻る